An estimated 279,100 people (women and men) in the U.S. will be diagnosed with invasive breast cancer. Breast cancer is the most common cancer in women, excluding skin cancer. An estimated 155,000+ patients currently live with “mets,” or metastatic breast cancer. This type of cancer, also called stage 4 breast cancer, means the cancer has metastasized, or traveled, through the bloodstream to create tumors in the liver, lungs, brain, bones and/or other parts of the body. Between 20 and 30 percent of women with early stage breast cancer go on to develop metastatic disease. While treatable, metastatic breast cancer (MBC) cannot be cured. The five-year survival rate for stage 4 breast cancer is 27% for woman and 22% for men; median survival is three years. Annually, the disease takes around 40,000 lives.1
The Swedish Cancer Institute’s multidisciplinary team offers extensive treatment options – Surgery, Hormonal therapy, Chemotherapy, Immunotherapy, Targeted therapy, Radiation therapy and numerous clinical trials. The main goals of metastatic breast cancer treatment are to make sure you have the:
• Longest survival possible with the disease
• Fewest possible side effects from the cancer and its treatment
• Best and longest quality of life possible
At the Cherry Hill location - the Swedish Radiosurgery Center physician’s innovative approach is a paradigm shift in treating MBC, utilizing CyberKnife, we successfully treat bone, lung, liver and brain metastases while the patient remains on systemic therapies.
The CyberKnife system uses the most advanced technology to precisely target the tumor within 1 mm accuracy. Which means we deliver a full dose to the target while minimizing exposing to surrounding areas. CyberKnife has revolutionized cancer treatment, it adjusts in real time to tumor or patient movement.
CyberKnife treatment improves overall survival with low or minimal side effect risks, prolonging progression free survival and extending the totality of treatment options available to our patients.
The Swedish Cancer Institute has many resources available to assist people with treatment options for Metastatic Breast Cancer. For more information on Swedish CyberKnife program, call 206-320-7187 and/or visit www.swedish.org/cyberknife.
1Statistics adapted from the American Cancer Society's (ACS) publication, Cancer Facts & Figures 2020 (January 2020), the ACS website (January 2020), and the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program (January 2020).
COMET trial (https://pubmed.ncbi.nlm.nih.gov/31426760/)